secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROKIDNEY CORP. (PROK)
CIK:        0001850270
Form:       8-K
Filed at:   2024-08-09T23:59:59+00:00
Accession:  0000950170-24-094341
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProKidney reports Q2 net loss $38.5M, cash $431.5M, restarts Phase 3 trials
---------------------------------------------------------------------------

- Interim Phase 2 REGEN-007 data show kidney function stabilization for 18 months in diabetes/advanced CKD patients.
- Manufacturing restarted; QP Declaration of Equivalence received in July; PROACT 1 and 2 trials resumed.
- Closed $140M upsized equity offering in June, extending cash runway into mid-2026.
- Cash & equivalents $431.5M at June 30, 2024 (vs $363.0M Dec 31, 2023).
- R&D expenses $29.4M (Q2 2024) vs $26.4M (Q2 2023); net loss $38.5M vs $34.8M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850270/000095017024094341/0000950170-24-094341-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850270/000095017024094341/prok-20240809.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-094341

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer